ARTICLE IN PRESS

Journal of Controlled Release xxx (2014) xxx-xxx



Contents lists available at ScienceDirect

Journal of Controlled Release



journal homepage: www.elsevier.com/locate/jconrel

1 Review

Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers

Q2 Manal A. Elsheikh ^{a,b}, Yosra S.R. Elnaggar ^{a,*}, Ossama Y. Abdallah ^a

Q3 ^a Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Egypt

6 ^b Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Egypt

ARTICLE INFO

8 Article history: 9 Received 5 July 2014

10 Accepted 21 August 2014

11 Available online xxxx

- 12 Keywords:
- 13 Cell line
- 14 Nanomedicine
- 15 Permeability
- 16 Cytotoxicity
- 17 Targeting

ABSTRACT

Nanomedicines are enjoying a widespread popularity realizing their intriguing potential to solve drug delivery 18 obstacles. Assessment of major quality attributes of nanocarriers is a crucial process for approving their therapeu-19 tic outcomes. Disparate assessment methods that recently encompassed cell line technique were employed . 20 Routinely, a cell line model was viewed as an excellent platform for gene and vaccine deliveries. However, its ap-21 plication in pharmaceutical assessment of nanocarriers was not so far overviewed. This review provides a metic-22 ulous look at cell culture implementations in evaluation of major quality attributes of nanocarriers, including oral 23 permeability, cytotoxicity and efficiency of tumor targeting. Among others, cell culture technique strikes the right 24 balance between predictability and throughput. It could circumvent drawbacks of in-vivo and in-vitro techniques 25 while gathering privileges of both. Imperative pharmaceutical considerations demanded for proper application of 26 this technique were emphasized. Furthermore, challenges encountered in assessment of versatile nanocarriers 27 were highlighted with proposed solutions. Finally, future research perspectives in this theme issue were 28 suggested. 29

© 2014 Elsevier B.V. All rights reserved.

36 Contents

30 **3**2 33

37	1.	Introduction	
38	2.	Terminology involved in cell culture methodologies	
39		2.1. Primary culture	
40		2.2. Cell line	
41		2.3. Sub-culture (passage, splitting)	
12		2.4. Passage number	
13		2.5. Confluency	
14		2.6. Anchorage dependence	
45		2.7. Monolayer and multilayer culture	
46	3.	Applications in nanocarrier assessment	
17		3.1. Permeability assessment	
18		3.1.1. In vivo methods	
19		3.1.2. Ex vivo gut sac technique	
50		3.1.3. In vitro method	
51		3.2. Assessment of cell cytotoxicity	
52		3.2.1. Principle	
53		3.2.2. Applications in nanomedicine	
54		3.3. Drug targeting	

Abbreviations: P-gp, P-glycoproteins; BEs, bioactive excipients; AP, apical; BL, basolateral; Papp, apparent permeability; CYP3A4, cytochrome P450 3A; HCC, hepatocellular carcinoma; BBB, blood–brain barrier; ER, Estrogen receptor.

* Corresponding author at: Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, Messalla Post Office, P.O. Box 21521, Alexandria, Egypt. Tel.: + 20 1147591065; fax: + 20 3 4873273.

E-mail address: yosra_pharm@yahoo.com (Y.S.R. Elnaggar).

http://dx.doi.org/10.1016/j.jconrel.2014.08.019 0168-3659/© 2014 Elsevier B.V. All rights reserved.

Please cite this article as: M.A. Elsheikh, et al., Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers, J. Control. Release (2014), http://dx.doi.org/10.1016/j.jconrel.2014.08.019

M.A. Elsheikh et al. / Journal of Controlled Release xxx (2014) xxx-xxx

55	4.	Future perspectives	0
56	5.	Conclusion	0
57	Refer	rences	0

58

2

1. Introduction 59

60 Major restrains of new and old drug moieties are manifested in poor oral bioavailability, harmful side effects, and lack of tissue targeting. 61 Nanomedicines have been recently employed to circumvent therapeu-62 tic obstacles of drug delivery. Unique characteristics of such nano-63 platforms like nanometric range, content of bioactive excipients (BEs), 64 and amenability for surface modification endow them to face numerous 65 66 therapeutic challenges. Versatile classes of nanocarriers with desperate properties comprised the core of our recent research, including 67 68 nanoemulsions, self-nanoemulsifying drug delivery system [1,2], liposomes and its modifications [3-5], solid lipid nanoparticles and nano-69 structured lipid carriers [6,7]. In addition, polymeric nanoparticles [8, 70 9], metal-based nanocarriers [10], and inorganic nanocarriers (carbon 71 nanotubes) are attracting intensified interest as well [11]. 72

73 Proper assessment techniques should be adopted to guarantee thera-74 peutic outcomes of nanocarriers. In the field of oral nanomedicine, assess-75ment of intestinal permeability is the most indicative for bioavailability 76and efficacy. Accordingly, many attempts were implemented to circumvent permeability related hurdles. These could be achieved either via in-7778 clusion of bioactive excipients (BEs) in the nanosystem or by using the 79whole system for lymphatic targeting. On the other hand, in view of parenteral nanocarriers, appraisal of targeting and uptake efficiency is the 80 81 most crucial parameter. In particular, high mortality rates were reported from side effects of anti-cancer drugs lacking targeting property. Thus, 82 83 appraisal of targeting efficiency of parenteral nanocarriers via both passive and active mechanisms is essential as well. For both cases (oral and 84 parenteral nanocarriers) cytotoxicity assessment would be badly re-85 quired. When an already existing molecule or compound, is reintroduced 86 87 in a nanomaterial form, it is considered as new chemical entity. Therefore, 88 an update has to be performed to include nanosystem specific properties 89 and toxicities [11,12] that was recognized as nanotoxicology. In a conseguence, characterization of major guality attributes of nanocarriers, in-90 cluding permeability, cytotoxicity and targeting potential deemed 91 92crucial for fulfilling proposed therapeutic outcomes via different adminis-93 tration routes.

In the context of nanocarrier assessment, different in-vivo and in-94 vitro methods have been employed. In recent research investigations, 95 96 cell culture technique could circumvent the drawbacks of in-vivo and 97 in-vitro methods while gathering privileges of both. Cell culture tech-98 nology was extensively employed in biochemical and immunological 99 research disciplines. It is one of the major tools used in cellular and molecular biology, providing excellent model systems for studying the nor-100 mal physiology and biochemistry of cells (e.g., metabolic studies, aging), 101 102 mutagenesis and carcinogenesis. In addition, cell culture medium was used in Hybridoma technology for mass production of monoclonal anti-103 bodies. Besides, cultured cells are used in viral vaccine production and 104 recombinant DNA technology either as a source of mRNA, gene se-105 quence or as vector. Recently, such techniques gained an enormous in-106 terest in the field of drug development and pharmaceutical assessment 107 of dosage forms with a recent highlight on nanocarriers [13]. 108

109 Cell culture is the process by which cells are cultivated under controlled conditions outside the living animal (in vitro) for easier experi-110 mental manipulation and regulation of controls [14]. This technique 111 offers privileges of reducing the animal's need, so it avoids the legal 112 and ethical problems of animal experimentation and related variations. 113 In addition, it avoids interference from biological molecules that occurs 114 in vivo, so different secretions and elements will be feasibly monitored. 115 116 Furthermore, homogeneous population of cells with similar growth re-117 quirements could be obtained. Therefore, cell characteristics will be maintained over several cell generations producing consistent and re- 118 producible results [13-15]. 110

Albeit cell culture technology was extensively utilized as a tool in 120 biomedical field, their pharmaceutical applications were not so far 121 overviewed. The rationale of the current review was to give an overview 122 on implementations of cell culture models in pharmaceutical assess- 123 ment of nanomedicines, with high emphasis on permeability assays, cy-124 totoxicity studies and targeting efficiency as major quality attributes. 125

2. Terminology involved in cell culture methodologies

Before proceeding in cell culture applications in nanomedicine, it 127 may be useful to summarize commonly used terminology of cell and tis- 128 sue culture. The following definitions will help to explain different types 129 of cultured cell, how to grow and expand cell population, in addition to 130 cell distribution in monolayer and multilayer culture. 131

126

139

160

2.1. Primary culture	132
2.1. I filliary culture	102

These are cells derived directly from intact or dissociated tissues or 133 organ fragments taken directly from an animal. The cells have heteroge- 134 neous nature, and retain many of the differentiated characteristics of the 135 original cells in vivo. However, most have a limited life span and ulti- 136 mately die. Until subculture, a culture is considered a primary one, 137 after that it is termed a cell line [13]. 138

2.2. Cell line

These cells are subcultured from primary cells but undergo manipu- 140 lation in the laboratory so that they can be propagated and passaged in- 141 definitely with no apoptosis. The term cell line denotes that it consists of 142 lineages of cells that originally exist in the primary culture, it also could 143 be referred as Established or Continuous cell line. Unlike the unmanip- 144 ulated primary cells, cell line may not mimic the original cells in in 145 vivo cells-after several passages-due to their manipulation. Tumor 146 cell lines are often derived from actual clinical tumors, for example 147 Coca-2 cell line which is derived from human colonic adenocarcinoma, 148 while in transformed cell lines, the transformation may be induced 149 using viral oncogenes or by chemical treatment. For example Hela cell 150 line (human epithelial cervical carcinoma) is transformed by human 151 papillomavirus 18 (HPV18) to immortalized cell line. Most normal 152 cells undergo limited number of subcultures, or passages before they 153 stop growing due to senescence, so that they are referred to as finite 154 cell lines, while tumor or transformed cell lines can divide more rapidly, 155 indefinitely, and form tumors when reintroduced into animals. Another 156 type of cell lines includes clonal cell line which is a cell population de- 157 rived from a single cell by successive mitoses forming a genetically ho-158 mogeneous population [13]. 159

2.3. Sub-culture (passage, splitting)

Sub-culture is the dissociation of cells from each other and from sub- 161 strate using proteolytic enzymes. Trypsin and/or EDTA are most com- 162 monly used in this process, so it is called trypsinization. Afterward, 163 these cells are transfered or transplanted to a new culture vessel with Q4 nutrition media so as to propagate and expand the cell population for 165 study. Reseeding this cell suspension generates a secondary culture, 166 which can be grown up and subcultured again to give a tertiary culture, 167 and so on. It is essential to determine, for each cell the type, source, and 168

Please cite this article as: M.A. Elsheikh, et al., Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers, J. Control. Release (2014), http://dx.doi.org/10.1016/j.jconrel.2014.08.019

Download English Version:

https://daneshyari.com/en/article/7864204

Download Persian Version:

https://daneshyari.com/article/7864204

Daneshyari.com